Floatz logo

FILGRASTIM

AIDS-related Peripheral/Systemic Lymphoma

National Cancer Institute (NCI)protein_peptidePhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the AIDS-related Peripheral/Systemic Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2BBB
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BBB
Procarbazine
AIDS Malignancy Consortium
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 1/2B
Hycamtin
National Cancer Institute (NCI)
Phase 2B

View all 23 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →